ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Patient selection for triplet therapy with darolutamide in metastatic castration-sensitive prostate cancer and patterns of administration: a Spanish multicenter study.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTriplet therapy with androgen deprivation therapy (ADT), docetaxel, and darolutamide is approved for treating patients with metastatic castration-sensitive prostate cancer (mCSPC) based on the results of the ARASENS trial. However, no guideline exists for patient selection beyond patient fitness for chemotherapy, personal preferences, disease volume, and metastases presentation. Evidence on patient selection and treatment administration in clinical practice is scarce. PATIENTS AND
methodsProspective, multicenter study conducted in Spain between November 2023 and June, 2024 in mCSPC patients selected for triplet therapy. Sociodemographic and clinical characteristics of patients at primary diagnosis, disease-related characteristics and symptoms at mCSPC diagnosis, and information on triplet therapy administration were collected. Descriptive statistics were used.
resultsDuring the study period, 105 patients from 15 Spanish hospitals were included in the study. The median age was 66 years (range 44-85). Ninety-three patients (88.6%) had synchronous disease. Most patients had ECOG-PS 0/1 (90.4%). Ninety-two (87.6%) patients had high-volume disease and 96 (91.4%) high-risk disease. Five (4.5%), 70 (67.3%), and 29 (27.8%) patients had M1a, M1b, and M1c disease, respectively. Bone (77.1%) and pelvic lymph node (70.5%) were the most frequent metastatic locations. Docetaxel and darolutamide were simultaneously initiated in 39 (37.1%) patients.
conclusionAs in the ARASENS trial, most patients offered triplet therapy in this representation of Spanish clinical practice were young and had synchronous disease. However, poorer disease characteristics, such as high-volume, high-risk disease, and involvement of visceral metastases, were more frequent. The rate of simultaneous initiation of darolutamide and docetaxel was low.
Indexed as
Identifiers
41485187What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.